![DePinho resigns as MD Anderson president, acknowledges shortcomings as administrator](https://cdn.cancerletter.com/media/2017/03/DePinho-web.jpg)
![DePinho resigns as MD Anderson president, acknowledges shortcomings as administrator](https://cdn.cancerletter.com/media/2017/03/DePinho-web.jpg)
Cover Story
Free
Ronald DePinho announced on March 8 that he will be stepping down as president of MD Anderson Cancer Center.DePinho's five-and-a-half years at the helm of the world's largest cancer center were marked by unprecedented turbulence, questions of conflicts of interest, and unhappiness on the part of the faculty.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Drugs & Targets
Trending Stories
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement. - At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago
- The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop